Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan in HFpEF with Pulmonary Hypertension (ARNIMEMS-HFpEF)
NCT04753112Phase 3Completed
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), pulmonary hypertension (PH), sponsored by Hospital Universitari Germans Trias i Pujol. Started Oct 2020; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT04753112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753112.